Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)
Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –
Biogen ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Biogen's ebitda for the twelve months ending Mar 31, 2022 was $3.01B, down 27.5% year over year. For fiscal 2021 it was $3.33B, down 33.5% from the year before. Over ten years it grew 4.8% a year on average. The highest annual figure on record is $7.51B in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $3.33B | -33.5% |
| FY2020 | Dec 31, 2020 | $5.01B | -33.3% |
| FY2019 | Dec 31, 2019 | $7.51B | +14.8% |
| FY2018 | Dec 31, 2018 | $6.54B | +1.7% |
| FY2017 | Dec 31, 2017 | $6.43B | +10.2% |
| FY2016 | Dec 31, 2016 | $5.83B | +6.2% |
| FY2015 | Dec 31, 2015 | $5.49B | +17.8% |
| FY2014 | Dec 31, 2014 | $4.66B | +52.9% |
| FY2013 | Dec 31, 2013 | $3.05B | +37.2% |
| FY2012 | Dec 31, 2012 | $2.22B | +6.6% |
| FY2011 | Dec 31, 2011 | $2.08B | +29.9% |
| FY2010 | Dec 31, 2010 | $1.60B | -6.9% |
| FY2009 | Dec 31, 2009 | $1.72B | +2.8% |
| FY2008 | Dec 31, 2008 | $1.68B | +44.4% |
| FY2007 | Dec 31, 2007 | $1.16B | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2022 | Mar 31, 2022 | $753.80M | -30.0% |
| Q4 FY2021 | Dec 31, 2021 | $721.80M | – |
| Q3 FY2021 | Sep 30, 2021 | $927.20M | -22.8% |
| Q2 FY2021 | Jun 30, 2021 | $602.90M | -71.1% |
| Q1 FY2021 | Mar 31, 2021 | $1.08B | -44.5% |
| Q4 FY2020 | Dec 31, 2020 | -$220.90M | -113.2% |
| Q3 FY2020 | Sep 30, 2020 | $1.20B | -43.8% |
| Q2 FY2020 | Jun 30, 2020 | $2.09B | +0.7% |
| Q1 FY2020 | Mar 31, 2020 | $1.94B | +19.5% |
| Q4 FY2019 | Dec 31, 2019 | $1.67B | +19.1% |
| Q3 FY2019 | Sep 30, 2019 | $2.14B | +4.5% |
| Q2 FY2019 | Jun 30, 2019 | $2.07B | +49.7% |
| Q1 FY2019 | Mar 31, 2019 | $1.62B | -4.7% |
| Q4 FY2018 | Dec 31, 2018 | $1.41B | -16.0% |
| Q3 FY2018 | Sep 30, 2018 | $2.04B | +11.6% |
| Q2 FY2018 | Jun 30, 2018 | $1.38B | +0.1% |
| Q1 FY2018 | Mar 31, 2018 | $1.70B | +10.9% |
| Q4 FY2017 | Dec 31, 2017 | $1.68B | +57.3% |
| Q3 FY2017 | Sep 30, 2017 | $1.83B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.38B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.54B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.06B | – |
See a number that looks wrong?